Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vascular Architects Inc.

Division of LeMaitre Vascular Inc.

Latest From Vascular Architects Inc.

Alternative Financing Strategies For Medtech Start-Ups

Pools of venture capital for life science companies are drying up. The good news is that there are alternative sources for young medtech companies. EBI convened a panel of experts at its recent IN3 conference to explain when and where to find them and presents here a Q&A with an angel investor, a representative from a venture debt firm, and an expert in non-dilutive grant funding.

Medical Device

US Markets for Nonvascular Stents

Lately, drug-eluting stents have downright monopolized all discussions of new stent technology, but there's a whole world of stenting outside of the interventional cardiology suite, and some of these clinical applications represent healthy markets for small companies. According to a report published in June by the Medtech Insight division of Windhover Information, "US Markets for Nonvascular Stents," sales of stents in several non-cardiology niche markets totaled approximately $152 million in 2005, a year in which stents were used in approximately 491,000 nonvascular endoluminal recanalization procedures. Overall, sales of these products are expected to grow at an annual compound rate of almost 3%, reaching approximately $174 million in the year 2010.
Medical Device

The New Math of Drug-Device Convergence

In combination products that span the device and pharmaceutical industry, one plus one doesn't necessarily equal three. Speaking at "Convergence: the Drug/Device Summit," Paul LaViolette, chief operating office of Boston Scientific, recounts the intricacies of getting Taxus, the largest combination product in history, to market. For all the success BSC has had, both with Taxus and generally speaking--a huge infrastructure, billions of dollars in revenues, and 18 PMA approvals under its belt-the first lesson it learned from its drug-eluting stent program was, "As hard as you think it may be, it's harder than that."
BioPharmaceutical Medical Device

Convergence: What's Next at the Nexus?

Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • LeMaitre Vascular Inc.
  • Senior Management
  • Allan May, Chmn. & CEO
    Sheila Heap , Dir., Bus. Dev., Europe
    Tom Douthitt, VP, Sales & Mktg.
    Kirti Kamdar, VP, R&D
  • Contact Info
  • Vascular Architects Inc.
    Phone: (408) 453-5150
    1830 Bering Dr.
    San Jose, CA 95112